US nod for Opdivo in pre-treated small cell lung cancer

US regulators have further expanded the scope of Bristol Myers Squibb’s Opdivo, approving its use for a previously treated small cell lung cancer.

Read on PharmaTimes

Europe’s first allogeneic stem cell therapy rejected by NICE

Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel - the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients.

Read on PharmaTimes

Cases of type II diabetes surge in under-25s

The number of children and young people being treated for type II diabetes has leapt by around 40 percent in just four years to more than 700 cases, NHS data show.

Read on PharmaTimes

Widespread confusion about cancer symptoms delaying diagnoses

Confusion about cancer symptoms among workers could be leading to delayed diagnoses and irregular self-examinations, suggests new research by Bupa UK.

Read on PharmaTimes

Don’t miss the 7 September deadline

The PharmaTimes Sales Awards closes for entry in just a few weeks and with Sanofi, Allergan, LEO Pharma, Novartis and Bio Products Laboratory and many more besides signed up to take part, all signs are pointing to a very exciting debut indeed. It only takes a few seconds to fill out the online entry form and entrants need not do anything else until the day of the competition.

Read on PharmaTimes

1 2 3

Top of page

Industry News

US regulators have further expanded the scope of Bristol Myers Squibb’s Opdivo, approving its use for a previously treated small...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us